medigraphic.com

2014, Number S2

Gac Med Mex 2014; 150 (S2)

Comparison between surveillance, adjuvant radiotherapy, or salvage radiotherapy after radical prostatectomy in patients with prostate cancer (PCa) in stage pT3 or higher and/or positive surgical margins

Rodríguez-Covarrubias F, Sotomayor-de-Zavaleta M, Castillejos-Molina R, Gabilondo-Navarro F, Feria-Bernal G

Language: Spanish
References: 16
Page: 140-144
PDF size: 211.99 Kb.


ABSTRACT

Objective: To assess the mid-term evolution of high-risk prostate cancer (PCa) initially treated with radical prostatectomy (RP) and to compare the role of surveillance and postoperative radiotherapy, either adjuvant (aRT) or salvage (sRT). Methods: Retrospective study of 390 patients with PCa treated with RP at our institution from February 1988 to December 2012. Those in stage pT3 or higher and/or with positive surgical margins (PSM) were included. They were divided in three groups: group 1, undergoing surveillance after RP; group 2 receiving aRT; and group 3 receiving sRT. Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method. Results: 156 patients were analyzed. Mean age was 63.8 ± 6.9 years (45-79). Mean follow-up was 58 ± 45 months; 71 (45.5%) had PSM, 40 (25.6%) were in stage pT3 or higher, and 45 (28.8%) had both features. Group 1 included 91 patients, group 2, 43 and group 3, 22. Initial prostate-specific antigen (PSA) was 12.8 ng/ml in group 1, 14.9 ng/ml in group 2, and 14.5 ng/ml in group 3 (p = 0.07). First postoperative PSA was 0.27, 0.87, and 0.50 ng/ml in group 1, 2 and 3, respectively (p = 0.007). Seven men died of PCa: three in group 1, three in group 2, and one in group 3 (p = 0.6). The CSS at five and 10 years was 100 and 89% for group 1, 95 and 80% for group 2, and 94 and 94% for group 3 (p = 0.71). Conclusion: Our results retrospectively show that surveillance, aRT and sRT are equivalent for the mid-term control of PCa after RP


REFERENCES

  1. International Agency for Research on Cancer. [Internet] Consultado el 5 de febrero de 2013. Disponible en: http://globocan.iarc.fr/factsheet.asp.

  2. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Eng J Med. 2012;366:981-90.

  3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-23.

  4. Rodríguez-Covarrubias F, Castillejos R, Sotomayor M, Gabilondo F, Feria G. The outcome of patients with prostate cancer and adverse pathological characteristics treated with radical prostatectomy. Eur Urol Suppl. 2008;7:251.

  5. Swanson GP, Basler JW. Prognostic factors for failure after prostatectomy. J Cancer. 2011;2:1-19.

  6. Epstein JI, Amin M, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005; 216:34-63.

  7. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572-8.

  8. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956-62.

  9. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J Clin Oncol. 2009;27:2924-30.

  10. Loeb S, Roehl K, Viprakasit D, Catalona W. Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol. 2008;54:88-94.

  11. Parker C, Sydes MR, Catton C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int. 2007; 99:1376-9.

  12. Sobin LH, Gospodariwicz M, Wittekind C. TNM classification of malignant tumors UICC International Union Against Cancer. 7.a ed. Wiley-Blackwell. Chichester, West Sussex, UK; 2009. p. 243-8.

  13. Stephenson AJ, Bolla M, Briganti A, et al. Postoperative radiation therapy for pathological advanced prostate cancer after radical prostatectomy. Eur Urol. 2012;61:443-51.

  14. Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy. EORTC 22911. J Clin Oncol. 2007;25:4178-86.

  15. Arceo-Olaiz R, de-Anda-González J, Urbina-Ramírez S, et al. Los márgenes quirúrgicos positivos disminuyen la supervivencia cáncer específica de los pacientes con cáncer de próstata tratados con prostatectomía radical: experiencia en un centro de tercer nivel en México. Gac Med Mex. 2013;149:286-91.

  16. King CR. Adjuvant versus salvage radiotherapy after prostatectomy: the apple versus the orange. Int J Radiation Oncology Biol Phys. 2012; 83:1045-6.




2020     |     www.medigraphic.com